@article{TsonevaMinevFrentzenetal.2017,
  author    = {Tsoneva, Desislava and Minev, Boris and Frentzen, Alexa and Zhang, Qian and Wege, Anja K. and Szalay, Aladar A.},
  title     = {Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis},
  series = {Molecular Therapy Oncolytics},
  volume    = {5},
  journal   = {Molecular Therapy Oncolytics},
  doi       = {10.1016/j.omto.2017.03.001},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-170786},
  pages     = {41-61},
  year      = {2017},
  abstract  = {Oncolytic vaccinia virus (VACV) therapy is an alternative cancer treatment modality that mediates targeted tumor destruction through a tumor-selective replication and an induction of anti-tumor immunity. We developed a humanized tumor mouse model with subcutaneous human tumors to analyze the interactions of VACV with the developing tumors and human immune system. A successful systemic reconstitution with human immune cells including functional T cells as well as development of tumors infiltrated with human T and natural killer (NK) cells was observed. We also demonstrated successful in vivo colonization of such tumors with systemically administered VACVs. Further, a new recombinant GLV-1h376 VACV encoding for a secreted human CTLA4-blocking single-chain antibody (CTLA4 scAb) was tested. Surprisingly, although proving CTLA4 scAb's in vitro binding ability and functionality in cell culture, beside the significant increase of CD56\(^{bright}\) NK cell subset, GLV-1h376 was not able to increase cytotoxic T or overall NK cell levels at the tumor site. Importantly, the virus-encoded β-glucuronidase as a measure of viral titer and CTLA4 scAb amount was demonstrated. Therefore, studies in our "patient-like" humanized tumor mouse model allow the exploration of newly designed therapy strategies considering the complex relationships between the developing tumor, the oncolytic virus, and the human immune system.},
  language  = {en}
}
@article{SzalayWeibelHofmannetal.2013,
  author    = {Szalay, Aladar A and Weibel, Stephanie and Hofmann, Elisabeth and Basse-Luesebrink, Thomas Christian and Donat, Ulrike and Seubert, Carolin and Adelfinger, Marion and Gnamlin, Prisca and Kober, Christina and Frentzen, Alexa and Gentschev, Ivaylo and Jakob, Peter Michael},
  title     = {Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer},
  series = {Journal of Translational Medicine},
  journal   = {Journal of Translational Medicine},
  doi       = {doi:10.1186/1479-5876-11-106},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-96016},
  year      = {2013},
  abstract  = {Background Malignant pleural effusion (MPE) is associated with advanced stages of lung cancer and is mainly dependent on invasion of the pleura and expression of vascular endothelial growth factor (VEGF) by cancer cells. As MPE indicates an incurable disease with limited palliative treatment options and poor outcome, there is an urgent need for new and efficient treatment options. Methods In this study, we used subcutaneously generated PC14PE6 lung adenocarcinoma xenografts in athymic mice that developed subcutaneous malignant effusions (ME) which mimic pleural effusions of the orthotopic model. Using this approach monitoring of therapeutic intervention was facilitated by direct observation of subcutaneous ME formation without the need of sacrificing mice or special imaging equipment as in case of MPE. Further, we tested oncolytic virotherapy using Vaccinia virus as a novel treatment modality against ME in this subcutaneous PC14PE6 xenograft model of advanced lung adenocarcinoma. Results We demonstrated significant therapeutic efficacy of Vaccinia virus treatment of both advanced lung adenocarcinoma and tumor-associated ME. We attribute the efficacy to the virus-mediated reduction of tumor cell-derived VEGF levels in tumors, decreased invasion of tumor cells into the peritumoral tissue, and to viral infection of the blood vessel-invading tumor cells. Moreover, we showed that the use of oncolytic Vaccinia virus encoding for a single-chain antibody (scAb) against VEGF (GLAF-1) significantly enhanced mono-therapy of oncolytic treatment. Conclusions Here, we demonstrate for the first time that oncolytic virotherapy using tumor-specific Vaccinia virus represents a novel and promising treatment modality for therapy of ME associated with advanced lung cancer.},
  subject      = {Lungenkrebs},
  language  = {en}
}
@article{PatilGentschevAdelfingeretal.2012,
  author    = {Patil, Sandeep S. and Gentschev, Ivaylo and Adelfinger, Marion and Donat, Ulrike and Hess, Michael and Weibel, Stephanie and Nolte, Ingo and Frentzen, Alexa and Szalay, Aladar A.},
  title     = {Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody},
  series = {PLoS One},
  volume    = {7},
  journal   = {PLoS One},
  number    = {10},
  doi       = {10.1371/journal.pone.0047472},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130039},
  pages     = {e47472},
  year      = {2012},
  abstract  = {Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for cancer therapy. We have previously reported that oncolytic vaccinia virus strains expressing an anti-VEGF (Vascular Endothelial Growth Factor) single-chain antibody (scAb) GLAF-1 exhibited significant therapeutic efficacy for treatment of human tumor xenografts. Here, we describe the use of oncolytic vaccinia virus GLV-1h109 encoding GLAF-1 for canine cancer therapy. In this study we analyzed the virus-mediated delivery and production of scAb GLAF-1 and the oncolytic and immunological effects of the GLV-1h109 vaccinia virus strain against canine soft tissue sarcoma and canine prostate carcinoma in xenograft models. Cell culture data demonstrated that the GLV-1h109 virus efficiently infect, replicate in and destroy both tested canine cancer cell lines. In addition, successful expression of GLAF-1 was demonstrated in virus-infected canine cancer cells and the antibody specifically recognized canine VEGF. In two different xenograft models, the systemic administration of the GLV-1h109 virus was found to be safe and led to anti-tumor and immunological effects resulting in the significant reduction of tumor growth in comparison to untreated control mice. Furthermore, tumor-specific virus infection led to a continued production of functional scAb GLAF-1, resulting in inhibition of angiogenesis. Overall, the GLV-1h109-mediated cancer therapy and production of immunotherapeutic anti-VEGF scAb may open the way for combination therapy concept i.e. vaccinia virus mediated oncolysis and intratumoral production of therapeutic drugs in canine cancer patients.},
  language  = {en}
}
@article{HeisigFrentzenBergmannetal.2011,
  author    = {Heisig, Martin and Frentzen, Alexa and Bergmann, Birgit and Gentschev, Katharina Ivaylo and Hotz, Christian and Schoen, Christoph and Stritzker, Jochen and Fensterle, Joachim and Rapp, Ulf R. and Goebel, Werner},
  title     = {Specific antibody-receptor interactions trigger InlAB-independent uptake of Listeria monocytogenes into tumor cell lines},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68705},
  year      = {2011},
  abstract  = {Background: Specific cell targeting is an important, yet unsolved problem in bacteria-based therapeutic applications, like tumor or gene therapy. Here, we describe the construction of a novel, internalin A and B (InlAB)-deficient Listeria monocytogenes strain (Lm-spa+), which expresses protein A of Staphylococcus aureus (SPA) and anchors SPA in the correct orientation on the bacterial cell surface. Results: This listerial strain efficiently binds antibodies allowing specific interaction of the bacterium with the target recognized by the antibody. Binding of Trastuzumab (Herceptin®) or Cetuximab (Erbitux®) to Lm-spa+, two clinically approved monoclonal antibodies directed against HER2/neu and EGFR/HER1, respectively, triggers InlABindependent internalization into non-phagocytic cancer cell lines overexpressing the respective receptors. Internalization, subsequent escape into the host cell cytosol and intracellular replication of these bacteria are as efficient as of the corresponding InlAB-positive, SPA-negative parental strain. This specific antibody/receptormediated internalization of Lm-spa+ is shown in the murine 4T1 tumor cell line, the isogenic 4T1-HER2 cell line as well as the human cancer cell lines SK-BR-3 and SK-OV-3. Importantly, this targeting approach is applicable in a xenograft mouse tumor model after crosslinking the antibody to SPA on the listerial cell surface. Conclusions: Binding of receptor-specific antibodies to SPA-expressing L. monocytogenes may represent a promising approach to target L. monocytogenes to host cells expressing specific receptors triggering internalization.},
  subject      = {Listeria monocytogenes},
  language  = {en}
}
@phdthesis{Frentzen2007,
  author    = {Frentzen, Alexa},
  title     = {Posttranskriptionale Regulation der Internalinexpression und alternative Internalin-unabh{\"a}ngige Aufnahme von Listeria monocytogenes in Animalzellen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-25631},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2007},
  abstract  = {Listeria monocytogenes ist ein weit verbreitetes, Gram-positives humanpatho-genes Bakterium, welches in immunsupprimierten Personen das Krankheitsbild der Listeriose ausl{\"o}sen kann. Der Infektionszyklus der Listerien im Wirt ist im Hinblick auf die Pathogenese dieses Erregers intensiv untersucht worden. Die Regulation der verschiedenen beteiligten Virulenzfaktoren unterliegt in L. monocytogenes einer starken Kontrolle, die einerseits durch regulatorische Proteine aber auch durch Umweltfaktoren beeinflusst wird. Die Mechanismen, die auf transkriptionaler wie auch auf translationaler Ebene die Expression verschiedener listerieller Virulenzgene regulieren, wurden k{\"u}rzlich n{\"a}her charakterisiert. Es wurden f{\"u}r verschiedene listerielle Virulenzgene Riboswitch-mechanismen zur Expressionskontrolle in Listerien neu beschrieben. Durch Vorarbeiten wurde auch f{\"u}r das inlAB-Operon ein posttranskriptionaler Regu-lationsmechanismus postuliert. Dabei wurde der anaerobe Stoffwechsel der Listerien als m{\"o}glicher Ausl{\"o}ser f{\"u}r die beobachtete Translationssteigerung des inlA- und inlB-Gens diskutiert. Innerhalb der vorliegenden Arbeit sollte nun weitergehend untersucht werden, in welchem Bereich der Sequenz des inlAB-Operons sich regulatorische Strukturen zur posttranskriptionalen Regulation unter anaeroben Wachstumsbedingungen befinden. Dazu wurden verschiedene Mutanten mit unterschiedlichen Deletionen im inlAB-Operon konstruiert und die Transkription und Translation sowohl des inlA-, als auch des inlB-Gens betrachtet. Eine Deletion im aroA-Gen bewirkt das Wachstum der Bakterien bei anaerobem Stoffwechsel. Diese Deletion wurde in die konstruierten St{\"a}mme eingef{\"u}gt, um die Expression der Gene unter den verschiedenen Wachstumsbedingungen vergleichen zu k{\"o}nnen. Außerdem wurden verschiedene gus-Reportergen-Fusionsmutanten und Promotor-austauschmutanten konstruiert, um quantitativ aussagekr{\"a}ftigere Daten zu erheben. Die Charakterisierung der Mutanten ließ erkennen, dass keiner der deletierten Bereiche des inlAB-Operons von L. monocytogenes f{\"u}r die beobachtete Translationssteigerung im inlA-Gen bei anaerobem Stoffwechsel verantwortlich zu sein scheint. Das inlB-Gen war innerhalb der hier gezeigten Experimente nicht posttranskriptional reguliert, wie im Vorfeld postuliert. Nach plasmidkodierter Expression verschiedener Bereiche des inlAB-Operons konnte, verglichen mit genomischer Expression, keine Ver{\"a}nderung in der inlA-Expression beobachtet werden. Die m{\"o}gliche Beteiligung eines potentiellen Regulatorproteins konnte innerhalb dieser Arbeit daher nicht n{\"a}her eingegrenzt werden. Auch ein Einfluss der regulatorischen Faktoren Hfq und CcpA auf die Expression des InlA Proteins in der L. monocytogenes \&\#916;aroA-Mutante konnte nicht gefunden werden. Es zeigte sich interessanterweise außerdem, dass weitere Virulenzgene wie actA und hly unter den anaeroben Bedingungen ebenfalls eine Translations-steigerung zeigten. Somit stellt sich abschließend die Frage, ob es sich bei der beobachteten Translationssteigerung des inlA-Gens wirklich um einen durch bestimmte Strukturen in der inlAB-mRNA ausgel{\"o}sten Mechanismus handelt. L. monocytogenes ist als intrazellul{\"a}r replizierendes, Gram-positives Bakterium interessant f{\"u}r den Einsatz in immun- und tumortherapeutischen Anwendungen. Attenuierte L. monocytogenes-St{\"a}mme wurden dazu bereits erfolgreich im Mausmodell als Tr{\"a}gerbakterien f{\"u}r Impfstoffstrategien eingesetzt. Die gezielte Infektion von Geweben ist jedoch aufgrund des wenig ausgepr{\"a}gten Zelltropismus der Listerien im Wirt bisher ein Problem f{\"u}r einen Einsatz in bakterienbasierten Anwendungen, wie z.B. der Tumor- oder Gentherapie. Innerhalb dieser Arbeit wurden L. monocytogenes-St{\"a}mme konstruiert, bei denen chromosomal das f{\"u}r die Integrase codierende Gen gegen das Gen f{\"u}r das Staphylokokken Protein A (SPA) unter der Kontrolle listerieller Promotoren ausgetauscht wurde. Die erfolgreiche Oberfl{\"a}chenlokalisation von Protein A in der Zellwand von Listerien konnte im Western Blot oder in funktionellen Immunfluoreszenzf{\"a}rbungen in Mikroskop- und FACS-Analysen nachgewiesen werden. Diese St{\"a}mme sollen im Cell Targeting zur gezielten Infektion von Geweben eingesetzt werden. Dazu konnten die Bakterien {\"u}ber Herceptin®-HER2/neu-vermittelte Adh{\"a}sion an SK-BR-3-Zellen erfolgreich in diese aufgenommen werden und innerhalb dieser replizieren. Die neu konstruierten Listeria-St{\"a}mme zeigten im Mausmodell keine Ver{\"a}nderung in ihrer Virulenz verglichen mit nicht-SPA-exprimierenden St{\"a}mmen. Die in dieser Arbeit vorgestellte Antik{\"o}rper-Rezeptor-vermittlelte Aufnahme der Listerien in Zellen stellt einen neuen, bisher nicht beschriebenen Mechanismus dar, der in vielen therapeutischen Anwendungen zur Infektion spezifischer Gewebe durch Listerien genutzt werden kann.},
  subject      = {Listeria monocytogenes},
  language  = {de}
}
@article{AdelfingerGentschevdeGuibertetal.2014,
  author    = {Adelfinger, Marion and Gentschev, Ivaylo and de Guibert, Julio Grimm and Weibel, Stephanie and Langbein-Laugwitz, Johanna and H{\"a}rtl, Barbara and Escobar, Hugo Murua and Nolte, Ingo and Chen, Nanhai G. and Aguilar, Richard J. and Yu, Yong A. and Zhang, Qian and Frentzen, Alexa and Szalay, Aladar A.},
  title     = {Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy},
  series = {PLoS ONE},
  volume    = {9},
  journal   = {PLoS ONE},
  number    = {8},
  doi       = {10.1371/journal.pone.0104337},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-119387},
  pages     = {e104337},
  year      = {2014},
  abstract  = {Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis. In summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great potential for effective treatment of FMC in animal model.},
  language  = {en}
}
@article{AdelfingerBesslerCeciletal.2015,
  author    = {Adelfinger, Marion and Bessler, Simon and Cecil, Alexander and Langbein-Laugwitz, Johanna and Frentzen, Alexa and Gentschev, Ivaylo and Szalay, Aladar A.},
  title     = {Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy},
  series = {Viruses},
  volume    = {7},
  journal   = {Viruses},
  doi       = {10.3390/v7072811},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125705},
  pages     = {4075-4092},
  year      = {2015},
  abstract  = {Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a novel approach for canine cancer therapy. Here we describe, for the first time, the characterization and the use of VACV strain GLV-5b451 expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as therapeutic agent against different canine cancers. Cell culture data demonstrated that GLV-5b451 efficiently infected and destroyed all four tested canine cancer cell lines including: mammary carcinoma (MTH52c), mammary adenoma (ZMTH3), prostate carcinoma (CT1258), and soft tissue sarcoma (STSA-1). The GLV-5b451 virus-mediated production of GLAF-2 antibody was observed in all four cancer cell lines. In addition, this antibody specifically recognized canine VEGF. Finally, in canine soft tissue sarcoma (CSTS) xenografted mice, a single systemic administration of GLV-5b451 was found to be safe and led to anti-tumor effects resulting in the significant reduction and substantial long-term inhibition of tumor growth. A CD31-based immuno-staining showed significantly decreased neo-angiogenesis in GLV-5b451-treated tumors compared to the controls. In summary, these findings indicate that GLV-5b451 has potential for use as a therapeutic agent in the treatment of CSTS.},
  language  = {en}
}